International Randomized Trials’ Attention to Locoregional Breast Cancer Control and Promise of Personal Genomics and Whole-Genome Scans for Personalized Approaches

Excerpt

Currently, there is major interest from surgeons and medical oncologists, researchers, scientists, physicians, and particularly patients in locoregional tumor control. Local and/or nodal recurrence may be the first isolated event after breast cancer treatment completion, influencing not only recurrence-free survival but also, in contrast with previous view, overall survival. In basic sciences, latest technological advances with cheaper DNA sequencing, genetics, personal genomics, genome-wide association studies, and pharmacogenomics hold major promise toward personalized recurrence risk stratification-based prevention of locoregional breast cancer.1,2 In routine clinical practice, fear and anxiety of patients about local ipsilateral breast cancer or new contralateral breast cancer are reflected in a dramatic increase of more aggressive surgery in the USA, aiming at prevention of local failures and improved overall survival.3,4 …